US5092885A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptides with laminin activity
Assignee: United States Department of Health and Human Services
•
Filing: 1988-11-16
•
Granted: 1992-03-03
•
Expires: 2008-11-16
Abstract
Abstract Peptides with laminin activity are provided as follows: tyrosine-isoleucine-glycine-serine-arginine; proline-aspartine-serine-glycine-arginine; and cysteine -aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissues, and inhibit in vivo tumor cell colonization of tissues.
Inventors
- 👤 Yoshihiko Yamada
- 👤 Jeannette O. Graf
- 👤 Yukihide Iwamoto
- 👤 Frank Robey
- 👤 Hynda K. Kleinman
- 👤 Makoto Sasaki
- 👤 George R. Martin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:28
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S623/00; Y10S623/924
Claims Analysis
Total Claims: 62
Claim 1
Independent Claim
38 words
Peptides having laminin-like activity selected from the group consisting of: (1) tyrosine-isoleucine-glycine-serine-arginine; (2) cysteine-aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine; (3) aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine; (4) glycine-tyrosine-isoleucine-glycine-serine-arginie; and derivatives thereof, said derivatives selected from the group consisting of amides, conjugates with proteins, cyclized peptides, and, polymerized peptides.
Claim 2
Dependent Claim
38 words
Peptides having laminin-like activity selected from the group consisting of: (1) tyrosine-isoleucine-glycine-serine-arginine; (2) cysteine-aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine; (3) aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine; (4) glycine-tyrosine-isoleucine-glycine-serine-arginie; and derivatives thereof, said derivatives selected from the group consisting of amides, conjugates with proteins, cyclized peptides, and, polymerized peptides.
Claim 3
Dependent Claim
17 words
An anti-metastatic agent for metastatic tumor cells comprising a peptide of claim 1 in a pharmaceutically carrier.
Claim 4
Dependent Claim
13 words
The agent of claim 2 wherein the tumor cells are lung carcinoma cells.
Claim 5
Dependent Claim
8 words
The agent of claim 2 comprising cyclized tyrosine-isoleucine-glycine-serine-arginine.
Claim 6
Dependent Claim
20 words
A carrier to target drugs to metastatic tumor cells comprising a peptide of claim 1 conjugated to an anti-cancer agent.
Claim 7
Dependent Claim
26 words
A method for inhibiting the formation of lung metastases comprising administering to an individual having lung cancer an effective amount of a peptide of claim 1.
Claim 8
Dependent Claim
35 words
A substrate active in promoting epithelial, endothelial, or neural cell attachment comprising a compound selected from the group consisting of a peptide of claim 1, its amide form, and its bovine serum albumin (BSA) conjugates.
Claim 9
Dependent Claim
33 words
A method for promoting increased adhesion of epithelial or endothelial cells to vascular prostheses and other artificial organs comprising coating the prostheses or organs with a composition comprising a peptide of claim 1.
Claim 10
Dependent Claim
11 words
The method of claim 8 wherein the peptide is cyclized tyrosine-isoleucine-glycine-serine-arginine.
Claim 11
Dependent Claim
20 words
An anti-adhesion factor for laminin-responsive epithelial cells comprising an antibody against a BSA conjugate of a peptide of claim 1.
Claim 12
Dependent Claim
29 words
A migration promoting factor for epithelial cells comprising a compound selected from the group consisting of a peptide of claim 1, amides of said peptides, and their BSA conjugates.
Claim 13
Dependent Claim
37 words
A method for promoting the migration of epithelial cells in a wound comprising administering to the wound a compound selected from the group consisting of a peptide of claim 1 and the amide forms of said peptides.
Claim 14
Dependent Claim
35 words
A migration inhibition factor for laminin responsive epithelial cells comprising a compound selected from the group consisting of a peptide of claim 1, the amide forms of said peptides, and BSA conjugates of said peptides.
Claim 15
Dependent Claim
51 words
A method for isolating the laminin cell surface receptor from detergent extracts of cells or of cell membranes bound to a laminin affinity column comprising adding to said cells or cell membranes a compound selected from the group consisting of a peptide of claim 1 and amide forms of said peptides.
Claim 16
Dependent Claim
23 words
A prosthetic device having a bilogically active surface which exhibits cell attachment activity, said surface having linked thereto a peptide of claim 1.
Claim 17
Dependent Claim
18 words
The prosthetic device of claim 15 wherein said biologically active surface constitutes a portion of a vascular graft.
Claim 18
Dependent Claim
16 words
The prosthetic device of claim 15 wherein said biologically active surface contains a synthetic resin fiber.
Claim 19
Dependent Claim
18 words
The prosthetic device of claim 15 wherein said biologically active surface comprises a portion of a percutaneous device.
Claim 20
Dependent Claim
31 words
A method for inhibiting the formation of blood vessel structures by endothelial cells comprising administering to a patient an effective amount of a peptide of claim 1 or its amide form.
Claim 21
Dependent Claim
20 words
A method for treating Kaposi's sarcoma comprising administering to a patient an effective amount of the peptide of claim 1.
Claim 22
Dependent Claim
8 words
The peptide of claim 1 which is tyrosine-isoleucine-glycine-serine-arginine.
Claim 23
Dependent Claim
12 words
The peptide of claim 21 wherein said derivative is an amide derivative.
Claim 24
Dependent Claim
8 words
The peptide of claim 1 with is cysteine-aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine.
Claim 25
Dependent Claim
8 words
The peptide of claim 1 which is aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine.
Claim 26
Dependent Claim
8 words
The peptide of claim 1 which is glycine-tyrosine-isoleucine-glycine-serine-arginine.
Claim 27
Dependent Claim
31 words
A peptide having laminin-like activity consisting of the sequence proline-aspartic acid-serine-glycine-arginine and derivatives thereof, said derivatives selected from the group consisting of amides, conjugates with proteins, cyclized peptides, and polymerized peptides.
Claim 28
Dependent Claim
31 words
A peptide having laminin-like activity consisting of the sequence proline-aspartic acid-serine-glycine-arginine and derivatives thereof, said derivatives selected from the group consisting of amides, conjugates with proteins, cyclized peptides, and polymerized peptides.
Claim 29
Dependent Claim
12 words
The peptide of claim 26 wherein said derivative is an amide derivative.
Claim 30
Dependent Claim
19 words
An anti-metastatic agent for metastatic tumor cells comprising a peptide according to claim 26 in a pharmaceutically acceptable carrier.
Claim 31
Dependent Claim
13 words
The agent of claim 28 wherein the tuor cells are lung carcinoma cells.
Claim 32
Dependent Claim
21 words
A carrier to target drugs to metastatic tumor cells comprising a peptide according to claim 26 conjugated to an anti-cancer agent.
Claim 33
Dependent Claim
15 words
The method of claim 6 wherein the derivative of said peptide is an amide derivative.
Claim 34
Dependent Claim
27 words
A method for inhibiting the formation of lung metastases comprising administering to an individual having lung cancer an effective amount of a peptide according to claim 26.
Claim 35
Dependent Claim
15 words
The method of claim 49 wherein the derivative of said peptide is an amide derivative.
Claim 36
Dependent Claim
32 words
A substrate active in promoting epithellial, endothelial, or neural cell attachment comprising a compound selected from the group consisting of a peptide of claim 26, its amide form, and its BSA conjugates.
Claim 37
Dependent Claim
15 words
The method of claim 8 wherein the derivative of said peptide is an amide derivative.
Claim 38
Dependent Claim
34 words
A method of promoting increased adhesion of epithelial or endothelial cells to vascular prostheses and other artificial organs comprising coating the prostheses or organs with a composition comprising a peptide according to claim 26.
Claim 39
Dependent Claim
16 words
The anti-adhesion factor of claim 10 wherin the antibody is specific to the B-chain of laminin.
Claim 40
Dependent Claim
30 words
A migration promoting factor for epithelial cells comprising a compound selected from the group consisting of a peptide according to claim 26, amides of said peptides, and their BSA conjugates.
Claim 41
Dependent Claim
37 words
A method for promoting the migration of eqithelial cells in a wound comprising administering to the wound a compound selected from the group consisting of a peptide according to claim 26 and amide forms of said peptides.
Claim 42
Dependent Claim
35 words
A migration inhibition factor for laminin responsive epithelial cells comprising a compound selected from the group consisting of a peptide according to claim 26, amide forms of said peptide, and BSA conjugates of said piptide.
Claim 43
Dependent Claim
51 words
A method for isolating the laminin cell surface receptor from detergent extracts of cells or of cell membranes bound to a laminin affinity column comprising adding to said cells or cell membranes compound selected from the group consiting of a peptide according to claim 26 and amide forms of said peptide.
Claim 44
Dependent Claim
24 words
A prosthetic device having a biologically active surface which exhibits cell attachemnt activity, said surface having linked thereto a peptide according to claim 26.
Claim 45
Dependent Claim
18 words
The prosthetic device of claim 42 wherein said biologically active surface constitutes a portion of a vascular graft.
Claim 46
Dependent Claim
16 words
The prosthetic device of claim 42 wherein said biologically active surface contains a synthetic resin fiber.
Claim 47
Dependent Claim
18 words
The prosthetic device of claim 42 wherein said biologically active surface comprises a portion of a percutaneous device.
Claim 48
Dependent Claim
15 words
A composition comprising a solid substrate having attached thereto a peptide according to claim 1.
Claim 49
Dependent Claim
19 words
The composition of claim 46 wherein the solid substrate is selected from the group consisting of nitrocellulose and polyester.
Claim 50
Dependent Claim
11 words
The composition of claim 46 wherein the solid substrate is agarose.
Claim 51
Dependent Claim
15 words
A composition comprising a solid substrate having attached thereto a peptide according to claim 26.
Claim 52
Dependent Claim
19 words
The composition of claim 49 wherein the solid substrate is selected from the group consisting of nitrocellulose and polyester.
Claim 53
Dependent Claim
11 words
The composition of claim 49 wherein the solid substrate is agarose.
Claim 54
Dependent Claim
12 words
A composition comprising a peptide according to claim 1 coupled to collagen.
Claim 55
Dependent Claim
11 words
The composition of claim 52 further comprising a pharmaceutically acceptable carrier.
Claim 56
Dependent Claim
23 words
The composition of claim 53 which is in a form selected from the group consisting of a lotion, salve, gel, colloid, and powder.
Claim 57
Dependent Claim
12 words
A composition comprising a peptide according to claim 26 coupled to collagen.
Claim 58
Dependent Claim
11 words
The composition of claim 55 further comprising a pharmaceutically acceptable carrier.
Claim 59
Dependent Claim
23 words
The composition of claim 56 which is in a form selected from the group consisting of a lotion, salve, gel colloid, and powder.
Claim 60
Dependent Claim
32 words
A method for inhibiting the formation of blood vessel structures by endothelial cells comprising administering to a patient an effective amount of a peptide according to claim 26 or its amide form.
Claim 61
Dependent Claim
21 words
A method for treating Kaposi's sarcoma comprising administering to a patient an effective amount of a peptide according to claim 26.
Claim 62
Dependent Claim
9 words
The peptide of claim 21 which is cyclized tyrosine-isoleucine-glycine-serine-arginine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-03 | 1995-09-02 | 1996-03-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-03 | 1999-09-02 | 2000-03-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-03 | 2003-09-02 | 2004-03-03 | $7700.00 | Window Closed / Lapsed |